Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23096934 | 0.76 | KDM1A (0.34) | CYP3A4CFTRGOPCALDH1A1 | |
| SCHEMBL30139970 | 0.76 | CYP3A4 (0.33) | CYP3A4CFTRGOPCALDH1A1MEN1 | |
| SCHEMBL9978052 | 0.76 | CFTR (0.31) | CYP3A4CFTRGOPCALDH1A1 | |
| SCHEMBL13782279 | 0.76 | CFTR (0.31) | CYP3A4CFTRGOPCALDH1A1 | |
| SCHEMBL24633078 | 0.76 | CFTR (0.31) | CYP3A4CFTRGOPCALDH1A1 | |
| SCHEMBL881116 | 0.76 | NR1H2 (0.51) | CYP3A4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL5545795 | 0.74 | CFTR (0.44) | CYP3A4CFTRGOPCMEN1KMT2A | |
| SCHEMBL29805714 | 0.73 | KDM1A (0.32) | — | |
| SCHEMBL14974744 | 0.72 | CFTR (0.32) | CYP3A4CFTRGOPC | |
| SCHEMBL28480148 | 0.69 | LMNA (0.42) | CYP3A4MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227207-A1 | COSMETIC COMPOSITIONS CONTAINING SUBSTITUTED AZOLE AND METHODS FOR ALLEVIATING THE SIGNS OF PHOTOAGED SKIN | THE PROCTER & GAMBLE COMPANY (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227207-A1 | COSMETIC COMPOSITIONS CONTAINING SUBSTITUTED AZOLE AND METHODS FOR ALLEVIATING THE SIGNS OF PHOTOAGED SKIN | TYR, CUTA, CDKN1A | CYP3A4 112/4885CFTR 4585/4885GOPC 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.